BETA BIONICS, INC..
Company
- Reports this week
- 2
- Active events
- 0
- Connections
- 20
What's happening
Earlier this month
One to three months ago
-
FDA released a warning letter regarding device failures involving Beta Bionics, Inc.Some support3 reports
-
Lawsuit filed by Beta Bionics, Inc. in the Central District of California.Some support3 reports
-
Beta Bionics, Inc. is accused of failing to accurately describe observations made by the FDA.Some support15 reports1 development inside
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around BETA BIONICS, INC. this week
News at the entities that move BETA BIONICS, INC. most-
FDA StructuralThe FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.Moves BETA BIONICS, INC.
-
SEC StructuralKeefe, Bruyette & Woods raised a price target while First Western Financial disclosed a CEO stock sale filing with the SEC.Moves BETA BIONICS, INC.
-
Wells Fargo Mentioned togetherWells Fargo confirmed on October 20, 2026, that it utilizes figures provided by the Associated Press for its reporting.Moves BETA BIONICS, INC.
-
Josh Wilson StructuralAudit Committee initiated an investigation into the CFO of Endava, while Josh Wilson addressed investor concerns regarding company losses.Moves BETA BIONICS, INC.
-
Truist Financial TransactionalTruist Financial analysts dropped the target price for Deckers Outdoor on July 24, 2026.Moves BETA BIONICS, INC.
-
Central District Shared contextIndictment filed in the Central District of California on October 1, 2026.Moves BETA BIONICS, INC.
Connections
The 11 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Beta Bionics, issuing clearances, warning letters, and Form 483s regarding its medical devices.
-
SEC Structural
Beta Bionics operates under the mandatory regulatory oversight and filing requirements of the U.S. Securities and Exchange Commission.
-
Josh Wilson Structural
Josh Wilson serves as legal counsel representing investors in a class action lawsuit involving Beta Bionics.
-
Truist Financial Transactional
Truist Financial assessed BETA Bionics, Inc. by adjusting its price targets and providing analyst coverage.
-
Ilet Structural
BETA BIONICS manufactures the iLet Bionic Pancreas, utilizing the location Ilet for its operations.
-
Wells Fargo Mentioned together
Wells Fargo provides market visibility and analyst coverage for Beta Bionics.
-
Central District Shared context
A lawsuit involving BETA BIONICS, INC. is pending within the jurisdiction of the Central District.
-
New York City Shared context
A lawsuit involving BETA BIONICS, INC. was filed within the jurisdiction of New York City.
Show all 11 connections
-
Irvine Shared context
Beta Bionics is headquartered and reports financial results from the location of Irvine.
-
New York Shared context
BETA BIONICS, INC. is involved in a legal action that takes place within the jurisdiction of New York.
-
company Transactional
BETA BIONICS filed a class action on behalf of purchasers.
History
Events by the month they beganSeptember 2026
4 events- FDA issued a Form 483 after inspecting Beta Bionics, while Josh Wilson represented investors in a class action suit.
- FDA released a warning letter regarding device failures involving Beta Bionics, Inc.
- Lawsuit filed by Beta Bionics, Inc. in the Central District of California.
- Beta Bionics, Inc. is accused of failing to accurately describe observations made by the FDA.
June 2026
3 events- Beta Bionics received FDA clearance for its iLet Bionic Pancreas device on August 21, 2025.
- Beta Bionics, Inc. reported results from its location in Irvine on July 30, 2025.
- Analysts cut price targets and issued rating notes for BETA BIONICS, which was required to file transaction disclosures with the SEC.